Upcoming for ADHD meds: Black box warning?

Article

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Peter S. Jensen, MD
Related Content
Centanafadine shows efficacy and tolerability for pediatric ADHD in phase 3 trial | Image Credit: © H_Ko - stock.adobe.com.

Centanafadine shows efficacy and tolerability for pediatric ADHD in phase 3 trial

Morgan Ebert, Managing Editor
August 29th 2025
Article
ADHD Medications: A Look at Their Safety Profile

ADHD Medications: A Look at Their Safety Profile

Joan Daughton, MD
August 29th 2025
Podcast
A pediatrician’s guide to breaking financial and health barriers with ABLE accounts | Image Credit: © Brian Jackson - stock.adobe.com.

Empowering children with disabilities: A pediatrician’s guide to breaking financial and health barriers with ABLE accounts

Christopher Connolly, MD, MBA, MS;Margeaux Naughton, MD
August 29th 2025
Article
Adolescents: Medical use for prescription stimulants increase, nonmedical use decreases | Image Credit: © DedMityay - © DedMityay- stock.adobe.com.

Adolescents: Medical use for prescription stimulants increase, nonmedical use decreases

Joshua Fitch, Senior Editor
August 29th 2025
Article
FDA revises labeling on extended-release stimulants for ADHD to include weight loss risk | Image Credit: Contemporary Pediatrics

FDA revises labeling on extended-release stimulants for ADHD to include weight loss risk

Joshua Fitch, Senior Editor
August 29th 2025
Article
Social media exposure tied to adolescent cannabis and dual substance use | Image Credit: © New Africa - stock.adobe.com.

Social media exposure linked to increased cannabis, dual substance use in adolescents

Morgan Ebert, Managing Editor
August 29th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.